Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial

Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial

Purpose: Addressing the epidermal growth factor receptor (EGFR)-pathway by the competitive receptor ligand cetuximab is a promising strategy in pancreatic cancer. In the prospective randomized controlled phase II PARC-study (PARC: Pancreatic cancer treatment with radiotherapy (RT) and cetuximab), we...

Full description

Bibliographic Details
Main Authors: Jakob Liermann, Marc Munter, Patrick Naumann, Amir Abdollahi, Robert Krempien, Juergen Debus
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Pancreatic cancer
Cetuximab
Locally advanced pancreatic cancer
Chemoradiation
Pancreatic ductal adenocarcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630822000167

Internet

http://www.sciencedirect.com/science/article/pii/S2405630822000167

Similar Items